DEF: BioVie Inc. Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing and Boost Investor Appeal

BioVie Inc. has called a Special Meeting of Stockholders for June 23, 2025, to vote on a reverse stock split aimed at increasing its share price to maintain Nasdaq listing compliance and potentially attract institutional investors.

Summary

• BioVie Inc. will hold a virtual Special Meeting of Stockholders on Monday, June 23, 2025, at 2:00 p.m. Pacific Time.
• The primary proposal (Proposal 1) is to grant the Board of Directors authority to effect a reverse stock split of the company's common stock at a ratio between 1-for-5 and 1-for-10, at their sole discretion, within one year of the Special Meeting.
• The main purpose of the reverse stock split is to raise the per-share trading price of the common stock to maintain compliance with Nasdaq's minimum bid price requirement of $1.00, as the last reported sales price on May 30, 2025, was $1.04 per share.
• The reverse stock split is also intended to enhance the appeal of the common stock to institutional investors and the general investing public, who may be reluctant to invest in lower-priced securities.
• If implemented, the reverse stock split will uniformly affect all outstanding common stock, reducing the number of issued and outstanding shares from 18,570,726 as of June 2, 2025, to between one-fifth and one-tenth of that amount.
• The number of authorized shares (800,000,000 common, 10,000,000 preferred) and par values ($0.0001 common, $0.001 preferred) will not change, which will significantly increase the number of authorized but unissued shares.
• Proposal 2 seeks approval to grant discretionary authority to adjourn the Special Meeting, if necessary, to solicit additional proxies to approve Proposal 1.
• The Board of Directors unanimously recommends voting FOR both Proposal 1 and Proposal 2.

Sentiment

Score: 4

Explanation: While the proposed reverse stock split addresses a critical Nasdaq listing compliance issue, it is often viewed as a negative signal by investors, reflecting underlying challenges with the company's stock price performance. The company explicitly states risks associated with the split, including no guarantee of sustained price increase or improved liquidity, and the potential for future dilution from increased authorized shares.

Positives

• The proposed reverse stock split is a proactive measure to maintain the company's listing on The Nasdaq Stock Market, which is crucial for market access, liquidity, and investor confidence.
• A higher per-share trading price may enhance the appeal of BioVie's common stock to institutional investors and investment funds, potentially leading to increased interest and trading liquidity.
• Maintaining Nasdaq listing helps avoid adverse consequences such as limited market quotations, 'penny stock' designation, reduced trading activity, and difficulties in raising future financing.

Negatives

• There is no assurance that the reverse stock split will increase the market price proportionally or result in a permanent increase, and the total market capitalization may decrease.
• The reverse stock split may result in some stockholders owning 'odd lots' (less than 100 shares), which can be more difficult or costly to sell.
• The increased proportion of authorized but unissued shares could have a dilutive effect on earnings per share and voting power if new shares are issued in the future.
• The company cannot assure that its shares will continue to qualify for listing on Nasdaq even after the reverse stock split.

Risks

• Risk of delisting from Nasdaq if the company fails to satisfy continued listing requirements, leading to limited market quotations, 'penny stock' designation, and reduced trading activity.
• The reverse stock split may not achieve its intended effect of increasing the market price proportionally or permanently, potentially leading to a lower market capitalization.
• The reverse stock split could result in stockholders owning odd lots, which may incur higher transaction costs or be more difficult to sell.
• There is no assurance that a higher stock price will attract institutional investors or improve trading liquidity.
• The increase in authorized but unissued shares could be used for future issuances that dilute existing stockholders' percentage ownership and voting power.

Future Outlook

The Board of Directors will have sole discretion to determine the exact reverse stock split ratio (between 1-for-5 and 1-for-10) and whether to implement it at all, prior to the one-year anniversary of the Special Meeting. The company anticipates needing to raise additional capital in the ordinary course of business, and the reverse stock split will increase the number of authorized but unissued shares available for such purposes.

Management Comments

• "YOUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR PROPOSAL 1 AND PROPOSAL 2 OUTLINED IN THE ACCOMPANYING PROXY STATEMENT."
• Cuong V Do, President and Chief Executive Officer, signed the Notice of Intent to Convene a Special Meeting.

Industry Context

Reverse stock splits are a common strategy employed by small-cap companies, particularly in the biotechnology and pharmaceutical sectors, to maintain compliance with stock exchange listing requirements (such as minimum bid price) when their stock price has fallen significantly. This is often a necessary step to preserve access to capital markets and institutional investment, as many funds have policies against investing in 'penny stocks' or delisted securities. While a reverse split addresses a technical listing issue, it does not inherently improve the company's underlying business fundamentals or financial performance.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, though their percentage ownership will remain largely the same (except for minor adjustments due to fractional shares).
• Maintaining Nasdaq listing through the reverse split is intended to benefit all stakeholders by preserving market access, liquidity, and potentially attracting broader investor interest.
• Employees may experience improved confidence if the company maintains its Nasdaq listing, which can be important for equity compensation and overall company stability.

Next Steps

• Stockholders to vote on Proposal 1 (Reverse Stock Split) and Proposal 2 (Adjournment) at the Special Meeting on June 23, 2025.
• If approved, the Board of Directors will determine the exact ratio and effective date of the reverse stock split within one year of the Special Meeting.
• The company will file a Current Report on Form 8-K with the SEC to report the final voting results of the Special Meeting.

Key Dates

Recommendation

Keywords

BioVie Inc., BIVI, reverse stock split, Nasdaq listing, proxy statement, corporate governance, shareholder meeting, stock market, delisting risk, capital raise, stock price, liquidity